tetano
Editor, Senior Moderator
Vaccine. 2017 Dec 5. pii: S0264-410X(17)31645-6. doi: 10.1016/j.vaccine.2017.11.061. [Epub ahead of print]
[h=1]Report on eighth WHO meeting on development of influenza vaccines that induce broadly protective and long-lasting immune responses: Chicago, USA, 23-24 August 2016.[/h] Ortiz JR[SUP]1[/SUP], Hickling J[SUP]2[/SUP], Jones R[SUP]3[/SUP], Donabedian A[SUP]4[/SUP], Engelhardt OG[SUP]5[/SUP], Katz JM[SUP]6[/SUP], Madhi SA[SUP]7[/SUP], Neuzil KM[SUP]8[/SUP], Rimmelzwaan GF[SUP]9[/SUP], Southern J[SUP]10[/SUP], Spiro DJ[SUP]11[/SUP], Hombach J[SUP]12[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] In August 2016, the World Health Organization (WHO) convened the "Eighth meeting on development of influenza vaccines that induce broadly protective and long-lasting immune responses" to discuss the regulatory requirements and pathways for licensure of next-generation influenza vaccines, and to identify areas where WHO can promote the development of such vaccines. Participants included approximately 120 representatives of academia, the vaccine industry, research and development funders, and regulatory and public health agencies. They reviewed the draft WHO preferred product characteristics (PPCs) of vaccines that could address prioritized unmet public health needs and discussed the challenges facing the development of such vaccines, especially for low- and middle-income countries (LMIC). They defined the data desired by public-health decision makers globally and explored how to support the progression of promising candidates into late-stage clinical trials and for all countries. This report highlights the major discussions of the meeting.
[h=4]KEYWORDS:[/h] Influenza; Nextgeneration influenza vaccine; Pandemic influenza vaccine; Seasonal influenza vaccine; Universal influenza vaccine; Vaccine development
PMID: 29221895 DOI: 10.1016/j.vaccine.2017.11.061
[h=1]Report on eighth WHO meeting on development of influenza vaccines that induce broadly protective and long-lasting immune responses: Chicago, USA, 23-24 August 2016.[/h] Ortiz JR[SUP]1[/SUP], Hickling J[SUP]2[/SUP], Jones R[SUP]3[/SUP], Donabedian A[SUP]4[/SUP], Engelhardt OG[SUP]5[/SUP], Katz JM[SUP]6[/SUP], Madhi SA[SUP]7[/SUP], Neuzil KM[SUP]8[/SUP], Rimmelzwaan GF[SUP]9[/SUP], Southern J[SUP]10[/SUP], Spiro DJ[SUP]11[/SUP], Hombach J[SUP]12[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] In August 2016, the World Health Organization (WHO) convened the "Eighth meeting on development of influenza vaccines that induce broadly protective and long-lasting immune responses" to discuss the regulatory requirements and pathways for licensure of next-generation influenza vaccines, and to identify areas where WHO can promote the development of such vaccines. Participants included approximately 120 representatives of academia, the vaccine industry, research and development funders, and regulatory and public health agencies. They reviewed the draft WHO preferred product characteristics (PPCs) of vaccines that could address prioritized unmet public health needs and discussed the challenges facing the development of such vaccines, especially for low- and middle-income countries (LMIC). They defined the data desired by public-health decision makers globally and explored how to support the progression of promising candidates into late-stage clinical trials and for all countries. This report highlights the major discussions of the meeting.
[h=4]KEYWORDS:[/h] Influenza; Nextgeneration influenza vaccine; Pandemic influenza vaccine; Seasonal influenza vaccine; Universal influenza vaccine; Vaccine development
PMID: 29221895 DOI: 10.1016/j.vaccine.2017.11.061